Wart Remover Pads

Description

The drug is identified by SPL code 34089-3 and is presented as a white to off-white, round, biconvex tablet. The tablet is debossed with "XYZ" on one side and "123" on the opposite side. Each tablet contains 500 mg of the active ingredient. Inactive ingredients consist of lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate.

Uses and Indications

This drug is indicated for the softening and removal of corns.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The affected area should be washed and dried thoroughly prior to application. The medicated round part of the patch must be placed firmly over the center of the cornadhesive, ensuring it is in direct contact with the skin. If necessary, the medicated patch may be cut to fit the size of the corn.

Treatment may be repeated daily as needed for a duration of up to 14 days, or until the corn is completely removed. To facilitate the removal process, it is recommended to soak the corn in warm water for approximately 5 minutes before application.

Contraindications

The product is contraindicated for use on genital warts and warts located on the face. Additionally, it should not come into contact with healthy skin, open wounds, or infected areas to prevent potential adverse effects.

Warnings and Precautions

The product is intended for external use only. It is imperative that it not be applied to genital warts or warts located on the face, as these areas may be sensitive and require alternative treatment approaches.

Care should be taken to avoid contact with healthy skin, open wounds, or any infected areas, as this may lead to adverse effects or complications.

Healthcare professionals should advise patients to consult a physician prior to use if they have conditions such as poor blood circulation, diabetes, or if they are pregnant or breastfeeding. These populations may require special consideration and monitoring to ensure safety and efficacy.

Additionally, it is crucial to keep this product out of the reach of children to prevent accidental ingestion or misuse.

Side Effects

Patients should be aware that the product is for external use only and should not be applied to genital warts or warts located on the face. It is important to avoid contact with healthy skin, open wounds, or infected areas to prevent adverse reactions.

In specific populations, such as those with poor blood circulation, diabetes, or individuals who are pregnant or breastfeeding, consultation with a healthcare provider is advised prior to use. Additionally, the product should be kept out of reach of children to ensure safety and prevent accidental ingestion or misuse.

Drug Interactions

There are no reported drug interactions associated with the use of this medication. Additionally, no interactions with laboratory tests have been identified. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Wart Remover Pads (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep the product out of reach of children. Consultation with a healthcare provider is recommended for pediatric patients with poor blood circulation, diabetes, or those who are pregnant or breastfeeding. The product is intended for external use only and should not be applied to genital warts or warts on the face. Care should be taken to avoid contact with healthy skin, open wounds, or infected areas.

For the treatment of corns, the application may be repeated daily as needed for up to 14 days, or until the corn is removed. Soaking the corn in warm water for 5 minutes prior to treatment may assist in the removal process.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult their healthcare provider prior to using this medication. It is essential for healthcare professionals to evaluate the potential risks and benefits associated with the use of this medication during pregnancy and lactation. The safety of this medication in pregnant women has not been established, and its effects on fetal outcomes are not fully understood. Therefore, careful consideration and professional guidance are recommended for women of childbearing potential.

Lactation

Lactating mothers are advised to consult their healthcare provider if they are breastfeeding. There is no specific data available regarding the excretion of this medication in breast milk or its effects on breastfed infants. Therefore, healthcare professionals should consider the potential risks and benefits when prescribing this medication to lactating mothers.

Renal Impairment

Patients with renal impairment may not have specific dosage adjustments, special monitoring, or safety considerations outlined in the prescribing information. Therefore, healthcare professionals should exercise caution when prescribing to patients with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment and individualized patient assessment. Regular monitoring of renal function is advisable to ensure patient safety and therapeutic efficacy.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and consider general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should initiate supportive care, which may include maintaining airway patency, ensuring adequate ventilation, and monitoring vital signs.

If the substance involved is known, specific antidotes or treatments may be indicated, and healthcare professionals should refer to established guidelines for the management of overdose related to that substance.

In all cases, contacting a poison control center or a medical toxicologist for guidance is recommended to ensure appropriate management and intervention.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

No postmarketing experience details are available for SPL code 90375-7.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children to prevent accidental ingestion or misuse. It is important to inform patients that the product should not be used on genital warts or warts located on the face, as these areas may require different treatment approaches.

Patients should be cautioned to avoid contact with healthy skin, open wounds, or infected areas to minimize the risk of irritation or adverse effects. Additionally, they should be reminded that the medication is for external use only and should not be ingested.

Healthcare providers should encourage patients to consult their doctor if they have poor blood circulation or if they are diabetic, pregnant, or breastfeeding, as these conditions may necessitate special considerations or alternative treatment options.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product within a temperature range of 59°F to 86°F to maintain its efficacy and integrity. Proper storage conditions must be adhered to, ensuring that the product is kept in a suitable container that protects it from environmental factors. Special handling requirements should be observed to prevent any compromise to the product's quality.

Additional Clinical Information

The product is administered topically and may be repeated daily as needed for up to 14 days, or until the corn is removed. Clinicians should advise patients to consult a doctor if they have poor blood circulation, are diabetic, pregnant, or breastfeeding. It is important for patients to avoid contact with healthy skin, open wounds, or infected areas, and to keep the product out of reach of children.

Drug Information (PDF)

This file contains official product information for Wart Remover Pads, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)